Introduction
Antipsychotic drugs (APDs) are the cornerstone for treating an expanding list of psychiatric disorders. Mostly prescribed for schizophrenia and bipolar disorder, they are also increasingly being used as therapies in pediatric and geriatric psychiatry. 1, 2 Their mechanism of action is believed to be largely because of modulation of particular receptors in the brain. The older, typical APDs predominately block D2 dopamine receptors. The newer, atypical APDs have a broader receptor binding profile, often also affecting the activity of serotonin and histamine receptors. 3 An additional way whereby APDs may improve symptoms of these psychiatric disorders is by increasing myelination of nerves through the upregulation of lipogenic genes. 4, 5 Many of these drugs have unwanted side effects, including weight gain, which may, at least in part, be explained by upregulation of lipogenic genes. 6 There are several reports, which show that APDs increase expression of genes involved in cholesterol and fatty acid synthesis in cultured cells derived from various tissues such as brain, liver, and adipose tissue, 4, [6] [7] [8] [9] [10] as well as in vivo. 11, 12 This upregulation is mediated through increased activation of master transcriptional regulators of lipid metabolism, such as sterol regulatory element binding proteins (SREBPs). 4, 6, 7 There are three isoforms of SREBP. SREBP-1c generally controls genes involved in the synthesis of fatty acids, phospholipids, and triglycerides (such as acetyl-coenzyme A carboxylase (ACC) and fatty acid synthase (FAS)), whereas SREBP-2 is primarily concerned with regulating genes involved in cholesterol synthesis and uptake (including 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and the low-density lipoprotein (LDL) receptor). SREBP1a has overlapping gene targets between SREBP-1c and SREBP-2. 13 Briefly, SREBP is produced in the endoplasmic reticulum (ER) as an inactive precursor bound to the cholesterol-sensing protein, Scap, which measures the amount of cholesterol in the ER membranes. When this falls below a critical threshold, 14 Scap accompanies SREBP to the Golgi apparatus in which SREBP is cleaved sequentially by two proteases. The active transcription factor produced is imported into the nucleus in which it upregulates lipogenic gene transcription. If cholesterol levels are above the critical threshold, the SREBP-Scap complex is held back in the ER by Insig, an ER retention protein, preventing lipogenic gene induction.
The major route by which cholesterol is delivered to most cells in vivo is through uptake of exogenous lipoproteins. LDL is the major cholesterol-carrying particle in the circulation, although other non-LDL lipoproteins serve the same cholesterol transport function in the brain. 15 After receptor-mediated endocytosis, the lipoprotein particle is degraded in lysosomes to liberate free (unesterified) cholesterol, which is then transported to other intracellular organelles, including the ER. The cholesterol that reaches the ER can be esterified by sterol O-acyltransferase 1 (SOAT-1, formerly known as ACAT-1) as a storage form of cholesterol, and/or be sensed by the SREBP-Scap-Insig system. 16 A shared characteristic of most APDs is that they are cationic amphiphiles; that is, they are positively charged by virtue of an amine group that can be protonated, and display both hydrophilic and hydrophobic properties. A number of cationic amphiphiles, which are not APDs, have been reported to inhibit cholesterol trafficking to the ER. 17, 18 For instance, one such compound, U18666A, first developed as a cholesterol synthesis inhibitor, 19 blocks the ability of LDL-derived cholesterol to stimulate cholesterol esterification 17 and suppresses activation of SREBP, 16 thus phenocopying the lysosomal storage disease, Niemann-Pick disease, type C (NPC). If APDs were to act similar to other amphiphilic compounds such as U18666A, they would be expected to impair trafficking of LDL-derived cholesterol to the ER. As a consequence, insufficient cholesterol would reach the ER cholesterol sensor, Scap, thereby resulting in an inappropriate activation of SREBP. This could potentially explain the observed upregulation of SREBP-target genes in response to APD treatment. 7 In this study, we aimed to test whether impairment of intracellular cholesterol trafficking is the mechanism by which APDs upregulate SREBP-target genes. To this end, we used a model cell line. Chinese Hamster Ovary (CHO) cells are commonly used in studies on cholesterol metabolism and trafficking. 16, 20, 21 Earlier cell culture studies showing effects of APDs on SREBP-target gene expression have been conducted in media containing full serum. 4, [6] [7] [8] [9] Here, we used lipoprotein-deficient serum (LPDS) supplemented with the major cholesterol-carrying particle in the bloodstream, LDL, to investigate this phenomenon under controlled conditions, using several approaches to gauge lipoproteinderived cholesterol delivery to the ER. We showed that a panel of typical and atypical APDs upregulate lipogenic gene expression by interfering with trafficking of lipoprotein-derived cholesterol to the cholesterol homeostatic machinery in the ER. C]-acetic acid (specific activity: 56.0 mCi mmol -1 ) were purchased from GE Healthcare (Chalfont St Giles, UK). IgG-7D4, a mouse monoclonal antibody against hamster SREBP-2 (amino-acids 32-250) 22 was prepared from a mouse hybridoma cell line (ATCC CRL-2198). Peroxidase-conjugated AffiniPure donkey anti-mouse IgG was obtained from Jackson Immuno Research (West Grove, PA). LPDS was prepared from newborn calf serum as described earlier.
Materials and methods

Materials
23 LDL (d ¼ 1.019-1.063 g ml -1 ) was isolated by standard ultracentrifugation techniques from the plasma of healthy male volunteers. 24 Butylated hydroxytoluene, clozapine, compactin (mevastatin), Dulbecco's phosphatebuffered saline (PBS), filipin III, haloperidol, methyl-bcyclodextrin, mevalonate, paraformaldehyde, pimozide, primers, protease inhibitor cocktail, risperidone, triparanol, U18666A (3b-[2-(diethylamino) ethoxy] androst-5-en-17-one), and ziprasidone hydrochloride monohydrate were obtained from Sigma-Aldrich (St Louis, MO, USA). Aripiprazole, olanzapine, and quetiapine hemifumarate were obtained from Toronto Research Chemicals Inc. (Ontario, Canada). pGL3-basic plasmid, phRL-TK plasmid, and Dual Luciferase Assay Reporter System were from Promega (Madison, WI, USA). SYBR Green SensiMix dT was from Quantace (Norwood, MA, USA). All solvents used for thin layer chromatography (TLC) were analytical reagent grade from Ajax Finechem (Taren Point, NSW, Australia). Chinese Hamster Ovary-7 (CHO-7) cells were a kind gift of Drs Michael S Brown and Joseph L Goldstein (UT Southwestern, Dallas). The NPC cells (2-2), generously provided by Dr Laura Liscum (Tufts University, Boston), were derived Antipsychotic drugs inhibit cholesterol trafficking and synthesis I Kristiana et al from mutagenized CHO-K1 cells. 25, 26 This cell line contains an extra nucleotide at position 1335 of Niemann-Pick disease, type C1 (NPC1, gene), resulting in a frameshift and early translation termination after the 450th amino acid. 27 The 24(S),25-epoxycholesterol (5-cholesten-24(S),25-epoxy-3b-ol) and cholesterol were obtained from Steraloids (Newport, RI, USA). Cholesterol complexed to methyl-bcyclodextrin was prepared as described.
23 GW70585X (lanosterol demethylase inhibitor) and GW534511X (oxidosqualene cyclase inhibitor) were kind gifts from Glaxo-Smith Kline (Stevenage, UK).
Cell culture and media CHO-7 cells were seeded in six-well plates at a density of 2 Â 10 5 cells per well for all experiments unless specified. They were grown as a monolayer (37 1C, 5% CO 2 atmosphere) in Dulbecco's Modified Eagle's Medium/ Ham's Nutrient Mixture F-12 containing penicillin (100 units ml -1 ), streptomycin (100 mg ml -1 ), and L-glutamine (2 mM), supplemented with 5% (v/v) LPDS (Medium A). The next day, cells were switched to pre-treatment media containing 5% (v/v) LPDS, 5 mM compactin, and 50 mM mevalonate (Medium B) for 16 h, before treatment with test agents. This same media was used for treatment with addition of various test agents (for example APDs, U18666A) as described, unless otherwise indicated. Test agents were added in ethanol or dimethylsulfoxide, and within an experiment, the final concentrations of solvent were kept constant between conditions and did not exceed 0.28% (v/v).
Quantitative real-time PCR CHO-7 cells were grown in triplicate in 12-well plates, pretreated overnight in Medium B, and treated for 6 h or 16 h as indicated. RNA was harvested using TRIzol reagent. RNA was reverse transcribed to yield cDNA using the SuperScript III First Strand cDNA Synthesis kit, and mRNA levels were determined relative to the housekeeping gene by quantitative real-time PCR using SYBR Green and a Corbett Rotorgene 3000. Primers given in Supplementary Table 1 were directed against acetyl-CoA carboxylase (this paper), HMG-CoA reductase, the LDL-receptor, FAS, with porphobilinogen deaminase (PBGD) as the housekeeping gene. Although not yet a standard procedure, it has been proposed that more than one housekeeping gene should be used for accurate normalization in quantitative real-time PCR. 29 In light of this recommendation, we also assayed two additional housekeeping genes (GAPDH and b-actin) in a subset of experiments. Both give very similar results to normalization with porphobilinogen deaminase. ), and L-glutamine (2 mM), supplemented with 5% (v/v) newborn calf serum (Medium C). Cells were treated for 16 h in the presence or absence of LDL (50 mg ml -1 ), washed once with PBS, and then treated for a further 2 h without LDL as indicated. After treatment, cells were washed once with PBS and then fixed with 4% (w/v) paraformaldehyde/PBS for 30 min. Cells were washed three times with PBS (5 min each) and quenched in 1.5 mg ml -1 glycine/PBS for 10 min. They were then stained with Filipin III (25 mg ml -1 ) for 30 min and washed three times with PBS (5 min each). Coverslips were mounted on slides using ProLong Gold Antifade reagent and visualized using the Olympus DP70 Digital Camera System (Center Valley, PA, USA).
Cholesterol esterification
The effects of APDs on LDL-derived cholesterol esterification in CHO-7 cells were investigated as described by Kristiana et al. 16 with minor modifications. Cells were pre-treated overnight in Medium B, treated in Medium B with various agents (for example APDs, U18666A) as indicated, and metabolically labeled with 1 mCi per well [1- 14 C]-palmitate for 6 h during treatment. Cells were then lyzed in 500 ml per well 0.1 M NaOH and neutralized with an equal volume of 0.1 M HCl. Methanol (2 ml) was added to the cell lysate and the lipids were extracted with hexane (2 ml) after vortex mixing. Extracts were dried and re-dissolved in hexane. Cell protein levels were determined in the cell lysate by the Bicinchoninic Acid assay (Pierce, Rockford, IL, USA). Lipid extracts, standardized for protein, were separated by TLC on Silica Gel 60 F 254 plates (Merck, Whitehouse Station, NJ, USA) with the mobile phase heptane:diethyl ether:glacial acetic acid (90:30:1, v/v/v). Bands corresponding to a cholesteryl ester standard were visualized using an FLA-5100 phosphoimager (Fujifilm, Tokyo, Japan). The relative intensities of bands were quantified using Sciencelab ImageGauge 4.0 Software (Fujifilm).
Analysis of SREBP-2 processing SREBP-2 processing was analyzed by western blotting as described 28 with minor modifications. After treatment, cells were washed once with PBS and then lyzed in lysis buffer (l00 ml per well: 10 mM Tris-HCl, pH 7.6, 100 mM NaCl, 2% (w/v) SDS) containing protease inhibitor cocktail (5 ml per well). Lysates were then homogenized by passing through a syringe needle (18 gauge, 30 times) and protein concentrations were measured by the Bicinchoninic Acid assay. Samples (60 mg protein) were mixed with 0.25 volumes of 5 Â SDS loading buffer. 23 After heating (95 1C, 5 min), they were separated by 10% SDS-PAGE and transferred to TransBlot Nitrocellulose filter (Bio-Rad, Hercules, CA, USA). Gels were calibrated with the Precision Plus Kaleidoscope Standard (Bio-Rad). SREBP-2 was probed using IgG-7D4 and bound antibodies were visualized by chemiluminescence with Immobilon HRP Reagents (Millipore, Billerica, MA, USA) and exposed to Hyperfilm ECL (GE Healthcare, Chalfont St Giles, UK). The relative intensities of the bands were quantified using ImageJ Software (1.36b).
Cholesterol and fatty acid synthesis assay
The effects of various APDs on cholesterol and fatty acid synthesis were investigated using TLC as described 28 with minor modifications. After 6 h treatment with the drugs, cells were washed twice with PBS. The treatments were then continued in the same media without compactin or mevalonate and metabolically labeled with 1 mCi per well [1- 14 C]-acetic acid for 2 h. Cells were then washed once with PBS, lyzed in 0.1 M NaOH (500 ml per well), and rinsed with an equal volume of H 2 O. The lysates were then saponified with 2 ml ethanol, 500 ml 75% (w/v) KOH, butylated hydroxytoluene (1 ml, 20 mM), and EDTA (20 ml, 20 mM) at 701C for 1 h. After cooling, the lipids were extracted with 2 ml hexane and evaporated to dryness. For cholesterol synthesis, lipids extracts were re-dissolved in 60 ml hexane and aliquots corresponding to equivalent amounts of protein were separated by argentation TLC using 4% (w/v) silver-coated Silica Gel 60 F 254 plates with a mobile phase of heptane:ethyl acetate (2:1, v/v), developed four times. For fatty acid synthesis, fatty acids were extracted into 2 ml hexane from the same samples after acidification with 10 M HCl (1.5 ml). Hexane extracts were evaporated and re-dissolved in 60 ml hexane and separated by TLC using Silica Gel 60 F 254 plates with a mobile phase of heptane:diethyl ether:glacial acetic acid (90:30:1, v/v/v). Bands corresponding to cholesterol or fatty acid standards were visualized using the FLA-5100 phosphoimager (Fujifilm, Tokyo, Japan). The relative intensities of bands were quantified using Sciencelab ImageGauge 4.0 Software (Fujifilm).
Liver X receptor promoter activity assay CHO-7 cells were grown in triplicate in 24-well plates, and transfected for 4 h in Medium A (lacking penicillin/streptomycin) with 250 ng 3 Â LXRE luciferase reporter plasmid 21 (or pGL3-basic empty vector) and 25 ng Renilla control plasmid (phRL-TK) using lipofectamine LTX. Cells were then treated for 16 h, washed with PBS and lyzed in passive lysis buffer (Promega). Luciferase activity was determined using the dual luciferase assay reporter system in a Veritas luminometer (Turner designs). Values were normalized for transfection efficiency using the Renilla control and expressed relative to vehicle-treated controls.
Data presentation and statistical analysis
For all graphs, data are presented as mean±s.e.m. from at least three separate experiments. Where appropriate, statistical differences were determined by paired Student's t-tests. A P-value o0.05 (two-tailed) was considered statistically significant. For each statistical significance shown in the figures, the corresponding t-and P-value as well as the number of degrees of freedom are given in Supplementary Table 2 .
Results
Induction of SREBP-target gene expression by haloperidol and pimozide occurs in the presence of lipoprotein-derived cholesterol, but not cholesterol complexed to cyclodextrin In our initial studies, we investigated two typical APDs: haloperidol and pimozide. Haloperidol was chosen because it is one of the earliest typical APDs (a butyriphenone), and was one of the original drugs of this class shown to upregulate SREBP gene expression. 4 Pimozide, an APD of the diphenylbutylpiperidine class, was included because we have found that it potently upregulates SREBP-target gene expression in a number of cell types. 10 The steroidal cationic amphiphile U18666A was incorporated into the experimental design as it is known to inhibit intracellular cholesterol trafficking. 16, 17 The chemical structures of these three drugs, shown in Supplementary Figure 1 , illustrate the amphiphilic nature of these compounds. HMG-CoA reductase and the LDL receptor were selected as two SREBP-2-target genes, and ACC and FAS were included as two SREBP-1c-target genes. 30 Cholesterol was added as lipoprotein (LDL), or solubilized with cyclodextrin, which bypasses the endosomal-lysosomal route taken by lipoprotein-derived cholesterol. 31 In both cases, cholesterol treatment for 6 h downregulated the SREBP-target genes (Figure 1a-d) , although ACC was less responsive than the other genes. Importantly, the three drugs (haloperidol, pimozide, and U18666A) upregulated all four genes when cholesterol was added as LDL, but not as the cholesterol/cyclodextrin complex. For example, haloperidol and pimozide increased HMG-CoA reductase gene expression four-to fivefold greater than LDL alone ( Figure  1a ). The addition of drugs in combination with LDL largely normalized gene expression to levels observed in the control lipoprotein-deficient condition. In this control condition, haloperidol and U18666A had no effect on gene expression, whereas pimozide had a slight upregulatory effect, which attained statistical significance for three out of the four genes tested. This effect of pimozide was independent of SREBP activation (Supplementary Figure 2) . Relative to the SREBP-target genes, there were minimal effects on SREBP-1c and SREBP-2 transcript levels ( Supplementary Figure 3) , suggesting that these effects were mediated at the level of SREBP activation. Overall, these results support the contention that APDs upregulate lipogenic gene expression by interfering with lipoprotein-derived cholesterol trafficking to the ER.
Haloperidol and pimozide induce intracellular accumulation of lipoprotein-derived cholesterol
The fluorescent probe filipin can be used to detect unesterified cholesterol in the cell by fluorescence microscopy. 32, 33 In Figure 2 , very little filipin staining was normally observed in CHO-7 cells in the presence of LDL. However, appreciable filipin staining was apparent intracellularly in NPC1-deficient cells, which is a hallmark of NPC disease, and has earlier been shown to be due to lipoproteinderived cholesterol in late endosomes/lysosomes. 32 Similar intracellular filipin staining patterns were observed when CHO-7 cells were treated with U18666A as noted before, 33 as well as the APDs: haloperidol and pimozide. These results indicate that haloperidol and pimozide, similar to U18666A, result in intracellular accumulation of lipoprotein-derived cholesterol.
Haloperidol and pimozide inhibit esterification of lipoprotein-derived cholesterol Cholesterol trafficking to the ER has traditionally been monitored by measuring cholesterol esterification, 17, 18 which is catalyzed by the ER resident enzyme, SOAT-1, in CHO cells. 34 The ability of the cationic amphiphile U18666A to impair esterification of lipoprotein-derived cholesterol is well documented. 16, 17 To determine whether APDs also inhibit lipoprotein-derived cholesterol movement to the ER, we investigated the effects of varying concentrations (0-10 mM) of haloperidol and pimozide on cholesterol esterification in combination with added LDL. U18666A was included as a positive control. Cholesterol esterification was only detected when LDL was added (Figure 3) , confirming that this assay represents esterification of lipoproteinderived cholesterol rather than cellular cholesterol. 16 Treatment with either haloperidol or pimozide resulted in a concentration-dependent decrease in cholesterol esterification stimulated by LDL (Figure 3) . Agreeing with earlier work, 16, 17 U18666A potently inhibited esterification of lipoprotein-derived cholesterol, as denoted by the circled 'U'. These data indicate that the APDs, haloperidol and pimozide, inhibit trafficking of cholesterol to SOAT-1 in the ER at low micromolar concentrations.
Haloperidol and pimozide inhibit the ability of lipoprotein-derived cholesterol to suppress SREBP-2 activation Apart from determining effects on cholesterol esterification, another way to monitor cholesterol transport to the ER is by assessing SREBP activation. In addition, earlier studies 4, 6, 7 and results in Figure 1 indicate that lipogenic gene upregulation by APDs occurs through SREBP activation. We focused on SREBP-2 because it tends to be less susceptible to transcriptional regulation over the timeframe studied than SREBP-1c, and a specific antibody is available, whereas commercial SREBP-1 antibodies recognize both the 1a and 1c isoforms. In the presence of LDL, SREBP-2 processing was suppressed, as shown by the increased level of precursor and decreased level of mature SREBP-2 shown in Figure 4 . Quantification of the relative mature SREBP-2 levels indicated that haloperidol and pimozide blocked LDL-mediated suppression of SREBP-2 processing in a concentration-dependent manner. U18666A displayed this effect at sub-micromolar concentrations as earlier reported. 16 A statin was included in these experiments to avoid potential confounding effects of the drugs on cholesterol synthesis. However, the drugs also inhibited the ability of lipoprotein to suppress SREBP-2 processing in the absence of statin (Supplementary Figure 2) . Moreover, the inappropriate increase in SREBP-2 processing in response to the drugs seemed to involve impaired transport of LDL-derived cholesterol as it was overcome by the addition of cholesterol complexed to cyclodextrin (Supplementary Figure 4) . Together, these findings further indicate that haloperidol and pimozide impair delivery of LDLderived cholesterol to the SREBP homeostatic machinery in the ER, providing an explanation for how APDs upregulate SREBP-target genes. Haloperidol and pimozide inhibit synthesis of cholesterol but not fatty acids Thus far, our experiments have supported the contention that APDs increase lipogenic gene expression by interfering with LDL-derived cholesterol transport to the cholesterolsensing machinery in the ER. Reduced ER cholesterol is registered by Scap, resulting in increased transcriptional activation of SREBP-target genes. 23 However, ER cholesterol levels can also be reduced by inhibiting cholesterol synthesis, such as by the statins. 28, 35 Moreover, several amphiphilic compounds that have been found to inhibit intracellular cholesterol trafficking have also been reported to inhibit cholesterol synthesis. For example, U18666A inhibits oxidosqualene cyclase and other enzymes in cholesterol synthesis. 19 Hence, we hypothesized that APDs also inhibit cholesterol synthesis. Haloperidol and pimozide inhibited synthesis of cholesterol (Figure 5a ), but not fatty acids (Figure 5b ). Treatment with these drugs resulted in the accumulation of a diverse array of compounds, presumably all intermediates in cholesterol synthesis (Supplementary Figure 5) .
We then investigated whether the upregulation of lipogenic gene expression observed with APD treatment may be at least in part because of their inhibitory effect on cholesterol synthesis. Earlier (Figures 1, 3 and 4) , a statin (compactin) was included in the treatment conditions to eliminate cholesterol synthesis as a potential variable. Therefore, we performed experiments on SREBP-target gene expression with treatments conducted in the absence of statin and for a longer duration (16 h) so as to increase the likelihood of observing effects on gene expression. Although all three drugs essentially abolished cholesterol synthesis (Figure 5a ), their effects on SREBP-target gene expression were diverse (Figure 5c-f) . Haloperidol had no effect on any of the SREBP-target genes tested. U18666A treatment caused small, but significant, reductions in two of the four genes (HMG-CoA reductase and LDL receptor). Only pimozide showed effects consistent with the hypothesis that upregulated lipogenic expression may be partially attributed to inhibition of cholesterol synthesis, in that three out of the Densitometric values for cholesterol esterification were normalized to the þ LDL (no drug) condition for each panel, which was set to 1. The data are presented as mean ± s.e.m. from three separate experiments.
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four genes were significantly increased (LDL receptor, ACC, and FAS). However, it should be noted that pimozide did not upregulate HMG-CoA reductase and the LDL receptor as much as statin treatment, and that pimizode, but not statin, upregulated ACC, suggesting that the effects of pimozide on expression of these SREBP-target genes may be independent of its effects on cholesterol synthesis. Although all three drugs ablated cholesterol synthesis, they had variable effects on SREBP-target gene expression. This indicates that inhibition of cholesterol synthesis is not the primary mechanism for APDs upregulating lipogenic genes.
A panel of atypical APDs inhibit cholesterol trafficking to the ER and cholesterol synthesis
The experiments above have focused on two typical APDs: haloperidol and pimozide. To determine whether their effects can be generalized to other APDs, we tested a panel of six of the most commonly prescribed atypical drugs. The chemical structures of these are given in Supplementary  Figure 6 , again illustrating their amphiphilic nature. Aripiprazole, clozapine, and quetiapine were tested at 10 mM. Olanzapine, risperidone, and ziprasidone had less pronounced effects at that concentration (data not shown) and were thus also tested at 25 mM. At these concentrations, all six drugs substantially inhibited esterification of LDL-derived cholesterol (Figure 6a) , and blunted the ability of LDL to suppress levels of mature SREBP-2 ( Figure 6b ). Further, we tested whether or not these atypical APDs also inhibited cholesterol synthesis, as we showed for haloperidol and pimozide (Figure 5a and b) . Aripiprazole and ziprasidone had the most pronounced effects on cholesterol synthesis (Figure 7a) , and also markedly inhibited fatty acid synthesis (Figure 7b) . Clozapine, quetiapine, olanzapine, and risperidone had no effects on fatty acid synthesis, but all 14 C]-fatty acids were visualized by phosphoimaging. Representative phosphoimages of cholesterol synthesis and fatty acid synthesis are shown. Densitometric values for cholesterol and fatty acid synthesis were normalized to the vehicle-treated control condition, which was set to 1. The data are presented as mean þ s.e.m. from three separate experiments. (c-f) CHO-7 cells were grown in Medium A and then treated for 16 h in Medium A with or without drug (10 mM haloperidol or pimozide; 0.3 mM U18666A; 5 mM statin (S, compactin)). RNA was harvested, reverse transcribed to cDNA, and levels were analyzed for SREBP-target gene expression normalized to housekeeping gene levels: (c) HMGR, HMG-CoA reductase; (d) LDLR, LDL receptor; (e) ACC, acetyl-coenzyme A carboxylase; (f) FAS, fatty acid synthase. Data are presented relative to the vehicle-treated control condition, which has been set to 1, and are mean þ s.e.m. from three separate experiments. *Significantly different (Po0.05 by paired t-test) from the vehicletreated control condition in each data set.
significantly reduced cholesterol synthesis. Therefore, inhibition of lipoprotein-derived cholesterol trafficking and cholesterol synthesis seems to be a class effect of APDs.
A panel of APDs do not induce lipogenic gene expression through liver X receptor Another possibility we tested was that the lipogenic effects were mediated through the liver X receptors (LXR). These ligand-activated transcription factors induce a myriad of genes, including ACC, FAS, and SREBP-1c itself. 36 The natural ligands for LXR include sterols made in the mevalonate pathway, including the oxysterol 24(S),25-epoxycholesterol 37 and the cholesterol biosynthetic precursor desmosterol. 38 Given that APD treatment results in the accumulation of a diverse array of intermediates/products of the mevalonate pathway (Supplementary Figure 5) , it is possible that these may include activators of LXR. Alternatively, the APDs may themselves act as LXR agonists. To investigate the effects of a panel of APDs on LXR transcriptional activity, we used a plasmid encoding three tandem repeats of the LXR response element driving a luciferase reporter. The 24(S),25-epoxycholesterol served as a positive control and statin treatment (compactin) served as a negative control. 21, 39 Treatment with U18666A and all but one of the APDs had no significant effect on LXR transcriptional activity (Supplementary Figure 7) . Aripiprazole decreased LXR transcriptional activity to a greater extent than observed with statin treatment, suggesting that aripiprazole may antagonize LXR directly or indirectly by generating an LXR antagonist. This striking result was not pursued further, as our findings indicate that an LXRmediated mechanism is not a significant mode by which APDs induce lipogenic genes.
Discussion
In this paper, we set out to investigate the molecular mechanism(s) by which APDs induce lipogenic gene expression. Overall, our results support the contention that the primary mechanism involves APDs disrupting intracellular trafficking of lipoprotein-derived cholesterol to the ER, which houses the homeostatic machinery that senses and responds to changes in cellular cholesterol status (Figure 8 ). This is supported by our findings that with APD treatment, LDL-derived cholesterol accumulates intracellularly, cannot be esterified by the ER resident enzyme SOAT-1, and does not suppress SREBP-2 processing, consequently inducing SREBP-target gene expression.
The intracellular accumulation of lipoprotein-derived cholesterol and its impaired ability to reach the cholesterol homeostatic machinery is reminiscent of what is observed in the lysosomal storage disease NPC. This is a progressive neurodegenerative disease associated with cholesterol accumulation in the liver, spleen, and brain. 40 So are there any features in common between patients with NPC and those using APDs? Apparently not, but perhaps APDs have not been prescribed for long enough to discern such effects. Of course, NPC is a genetic disorder (with defects in NPC1 or NPC2) and hence operates during crucial stages of development. In this context, it is noteworthy that APDs are increasingly being prescribed in childhood, 1 when extensive brain development and remodeling occur, which is a potential concern in light of our results. Of course, transferring results from cultured cells to a clinical setting is a big step, and our findings first need confirmation in animal studies and eventually in patients.
An important distinction between APD treatment and NPC is our finding that these drugs inhibit cholesterol synthesis ( Figures 5, 6 ), whereas NPC tends to be associated with increased cholesterol synthesis.
41 Surprisingly, very little has been published on APDs inhibiting sterol synthesis. A high concentration of haloperidol (400 mM) inhibited ergosterol synthesis in yeast, resulting in accumulation of ergosta-8,14-dien-3b-ol, which pointed to an inhibitory effect on the yeast ERG24 gene product, namely 3b-hydroxysterol D14-reductase. Furthermore, haloperidol inhibited the activity of the yeast version of sterol D8,7 reductase, but not the mammalian version expressed in yeast. 42 While this paper was under review, Sánchez-Wandelmer et al. 43 reported that haloperidol (10 and 50 mM) inhibited cholesterol synthesis in SH-SY5Y neuroblastoma cells, leading to a build-up of sterol intermediates. Analogous to the yeast study, the pattern of accumulation was consistent with inhibition of the 3b-hydroxysterol D14-reductase. Our studies extend these reports, showing that a range of APDs inhibit cholesterol synthesis, with concomitant accumulation of sterol intermediates.
The inhibition of cholesterol synthesis potentially has important clinical implications. Lipids and defects in lipid metabolism are an emerging facet of the neurodevelopmental theory of schizophrenia. 5, 44, 45 Thus, it has been proposed that some APDs may have a beneficial effect on cognitive dysfunction in schizophrenia through lipogenic activation and myelination of the brain. 4, 45, 46 Our results indicate that although APDs induce lipogenic gene expression, this may not necessarily translate to increased synthesis of myelin, which comprises 70-80% of brain cholesterol. 47 We ruled out LXR as a significant contributor to the lipogenic gene upregulation observed with APDs, showing that none of the APDs tested increased LXR transcriptional activity. Furthermore, the fact that APDs upregulate not only ACC and FAS (both LXR and SREBP-target genes), but also HMG-CoA reductase and the LDL receptor (SREBP, but not LXR-target genes), implies that the mechanism is mediated through SREBP activation and not LXR.
All of the APDs studied can be classified as hydrophobic amines or cationic amphiphiles/amphipaths. Therefore, it is likely that the effects of APDs on LDL-derived cholesterol trafficking and cholesterol synthesis represents a class effect, because similar effects have been reported with analogous compounds, such as U18666A, chloroquine, imipramine, and trifluoroperazine. 18, 48 It should be noted that these (Figures 3 and 6) , and permitting the activation of SREBP (Figures 4 and 6) , thus inducing the expression of lipogenic SREBP-target genes (Figure 1 ). effects are not restricted to compounds with a positive charge. The fact that sterol intermediates accumulate in response to APDs (Supplementary Figure 5) , suggests that their inhibitory actions occur beyond HMG-CoA reductase. This may be through direct inhibition of later enzymes in cholesterol biosynthesis, and/or even by disrupting shuttling of precursors between the ER and plasma membrane, which has been shown to occur. 49 The precise molecular mechanism whereby amphiphiles exert their effects remains a mystery. One possibility is that these compounds directly interact with specific proteins, analogous to cholesterol binding to Scap, 50 oxysterols to Insig, 51 or cyclopamine binding to Smoothened in the Hedgehog pathway. 52 Indeed, Adams et al. 53 reported that the antipsychotic amphiphile chlorpromazine mimics cholesterol by binding to Scap. This should theoretically suppress SREBP processing and downregulate lipogenic gene expression. However, in keeping with this and other studies, 4, 6, 7 the cholesterol-mimicking effect of APDs could not be reproduced in intact cells. 53 Another possibility is that amphiphiles exert their effects by altering membrane properties. Thus, Cenedella et al. 54 using the enantiomer of U18666A showed comparable effects on cholesterol synthesis and apoptosis as the regular isomer. As enantiomers share the same chemical and physical properties, their effects on membrane structure should be identical, whereas their actions on processes that are stereoselective, as might be expected for specific protein interactions, should be different. 55 Cenedella et al. 54 concluded that U18666A likely works through membrane effects. Whether or not this amphiphile exerts membrane effects at the nanomolar concentrations required to observe effects on intracellular cholesterol trafficking remains to be seen. The fact that the profile of sterol intermediates formed in response to APDs is complex and diverse for different APDs (Supplementary Figure 5) , points to multiple steps in cholesterol biosynthesis being affected differentially. Further studies will be required to determine precisely how amphiphiles affect cellular cholesterol metabolism.
In these studies, we investigated effects of APDs with respect to LDL-derived cholesterol trafficking in model CHO cells. However, the idea that APDs inhibit movement of lipoprotein-derived cholesterol should be generalizable to most cell types, including those of the brain in which other lipoproteins serve the same function as LDL and traffic through the same endosomal-lysosomal system. 15 Indeed, we have shown that haloperidol, pimozide, and clozapine all lead to intracellular accumulation of lipoprotein-derived cholesterol in human cell lines of brain and hepatic origins (Supplementary Figure 8) .
The therapeutic relevance of the concentrations of APDs shown to induce lipogenic gene expression has been discussed at length by Ferno et al. 7 Peak plasma concentrations vary markedly between drugs and are substantially lower than found in target tissues. We found that haloperidol and pimozide exert effects at low micromolar concentrations. Other drugs were tested at higher concentrations, comparable with those used in earlier studies. 6, 7, 9 It is noteworthy that increased expression of lipid biosynthetic genes was detected in peripheral blood cells from olanzapine-treated patients, 11 supporting the contention that these effects may occur at therapeutically relevant concentrations.
In conclusion, we addressed three possible mechanisms to account for the observed action of APDs to induce lipogenic gene transcription. We argue that both LXR and inhibition of cholesterol synthesis are unlikely to be major contributors to these effects. We conclude that the major mechanism whereby APDs upregulate SREBP-target gene expression is by disrupting delivery of lipoprotein-derived cholesterol to the ER, which accommodates the cholesterol homeostatic machinery (Figure 8 ).
